Skip to main content

Table 2 Cox proportional hazards model for prognostic factors analysis in neuroblastoma patients (TMA)

From: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Variables Favorable/Unfavorable Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender female /male 0.893 (0.430–1.856) 0.762   
Age (month)  ≤ 18/ > 18 2.549 (1.083–5.997) 0.032 2.029 (0.778–5.289) 0.148
Pathological histotype ganglioneuroblastoma/ neuroblastoma 0.538 (0.249–1.161) 0.114   
MYCN amplification no/yes 6.973 (2.880–16.878)  < 0.001 3.299 (1.097–9.923) 0.034
Preoperative chemotherapy no/yes 5.219 (2.200–12.382)  < 0.001 1.144 (0.297–4.406) 0.845
Tumor stage (INSS) 4 s + 1 + 2/3 + 4 8.691 (3.397–22.237)  < 0.001 2.676 (0.780–9.180) 0.118
XPO1 expression low/high 10.652 (4.330–26.204)  < 0.001 4.392 (1.641–11.754) 0.003
  1. Cox regression was used for statistical analysis. 95%CI 95% confidence interval, HR Hazard ratio, INSS International Neuroblastoma Staging System